Guide to heart failure management strategies: A Clinical Evidence Review

How heart failure is classified and assessed

Heart failure is a clinical syndrome in which the heart cannot meet the body’s metabolic demands because of low cardiac output, elevated filling pressure, or both. Assessment commonly combines clinical examination with blood testing, imaging, echocardiography, chest radiography, and, when needed, hemodynamic evaluation. Causes and aggravating factors may include structural disease, rhythm disorders, ischemia, kidney disease, iron deficiency, medication nonadherence, or substance use, so treatment begins with identifying the underlying contributors rather than treating symptoms in isolation. 1

Clinical staging separates people at risk from those with structural disease, symptomatic heart failure, or advanced disease requiring specialized therapies. Ejection fraction helps guide treatment, but it is only one part of the assessment. Kidney function, potassium, blood pressure, heart rate, rhythm, congestion, functional capacity, comorbidities, and personal goals can all change the balance between benefit and risk. A management plan therefore requires periodic reassessment, particularly after hospitalization or medication changes. 2

Medication strategies for reduced ejection fraction

For many eligible adults with heart failure with reduced ejection fraction, guideline-directed medical therapy is built around four foundational classes: an angiotensin receptor-neprilysin inhibitor, or an ACE inhibitor or ARB when appropriate, an evidence-based beta blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor. These therapies target different biological pathways and are generally introduced and adjusted under clinical supervision. Rapid optimization may improve outcomes, but dosing must account for blood pressure, kidney function, potassium, heart rate, symptoms, and tolerance. 3

SGLT2 inhibitors have demonstrated benefits in many patients with reduced ejection fraction, including some people without diabetes, while beta blockers and renin-angiotensin system therapies remain central disease-modifying treatments. Mineralocorticoid receptor antagonists require attention to potassium and renal function. Other medicines, including digoxin, vasodilators, sinus-node inhibitors, or soluble guanylate cyclase stimulators, may be considered in selected circumstances. Medication education should cover adherence, renewal, adverse effects, and when to contact a clinician. 4

Managing congestion and daily symptoms

Loop diuretics are commonly used when fluid retention causes leg swelling, abdominal fullness, rapid weight gain, or breathlessness. Their principal role is symptom relief and control of volume status, rather than replacement of disease-modifying therapy. Clinicians must balance persistent congestion against excessive diuresis, which can contribute to low blood pressure, kidney dysfunction, dizziness, or electrolyte disturbances. Optimizing diuretic dosing is particularly important because congestion can make other therapies harder to tolerate. 5

Self-monitoring can help identify changing fluid status between appointments. A care team may provide individualized instructions about daily weight, swelling, breathlessness, dietary sodium, and fluid intake, because appropriate limits differ according to the patient’s condition. Rapid weight gain, worsening shortness of breath, increasing swelling, chest pain, fainting, or confusion should prompt urgent clinical advice or emergency evaluation. Medication changes should not be made independently because both under-treatment and over-diuresis can be harmful. 6

Approaches for preserved and mildly reduced ejection fraction

Management of heart failure with preserved or mildly reduced ejection fraction emphasizes relieving congestion and treating the conditions that drive symptoms and hospitalization. Common targets include hypertension, atrial fibrillation, coronary disease, obesity, diabetes, kidney disease, and other cardiovascular-kidney-metabolic contributors. SGLT2 inhibitors are now an important treatment option for many eligible patients across the ejection-fraction spectrum, while other therapies may be considered for selected clinical profiles. 7

Evidence in preserved and mildly reduced ejection fraction has expanded after many earlier trials failed to show definitive benefits from neurohormonal treatments. Recent reviews describe growing interest in non-steroidal mineralocorticoid receptor antagonists and incretin-based therapies for selected patients, but eligibility, regulatory status, contraindications, and long-term monitoring remain important. These therapies should be interpreted within the patient’s complete medical profile rather than applied as a uniform regimen to everyone with a similar ejection fraction. 3

Lifestyle, follow-up, and prevention of deterioration

Lifestyle management is an adjunct to medical treatment, not a substitute for it. Common elements include tobacco avoidance, physical activity or cardiac rehabilitation when clinically suitable, vaccination according to recommended schedules, attention to dietary sodium, and an individualized fluid plan. Weight management, blood-pressure control, diabetes care, and treatment of sleep or rhythm disorders may reduce additional strain on the cardiovascular system. Exercise recommendations should reflect stability, symptoms, functional capacity, and clinician assessment. 8

Follow-up is especially important during the period of medication initiation and titration. Monitoring may include symptoms, weight, blood pressure, heart rate, renal function, potassium, and adherence barriers. Vulnerable populations may face cost, transport, health-literacy, cultural, or access obstacles that make complex regimens difficult to maintain. Clear written instructions, medication reconciliation, coordinated primary and specialist care, and early review after discharge can reduce avoidable gaps in treatment. 4

Devices, hospitalization, and advanced care

Implantable cardioverter-defibrillators and cardiac resynchronization therapy may be considered for selected patients whose reduced ejection fraction, symptoms, rhythm, electrical conduction pattern, response to medication, and expected survival meet relevant criteria. These interventions are not routine replacements for medical therapy. Decisions require evaluation of potential benefits, procedural risks, comorbidities, life expectancy, and the patient’s preferences, with reassessment when ventricular function or clinical status changes. 1

Acute decompensation may require hospital-based treatment for congestion, low output, respiratory compromise, or serious rhythm abnormalities. Persistent or advanced heart failure should prompt referral to a specialized team to assess ventricular assist devices, transplantation, palliative care, or clinical trials. Advanced care planning can address symptom relief, hospitalization preferences, caregiver needs, and quality-of-life goals. The overall strategy is dynamic: stabilization, disease modification, surveillance, and supportive care may all be needed over time. 6

Sources

1. Merck Manual Professional Edition, Chronic Heart Failure
2. MSD Manual Professional Edition, Medications for Heart Failure
3. Heart Failure Reviews, Heart failure evidence update 2026
4. Medicine Today, Heart failure with reduced ejection fraction: a 2026 update on management
5. The Cardiology Advisor, Heart Failure Management: Current Approaches and Future Directions
6. Merck Manual Professional Edition, Overview of Heart Failure
7. Medaptly, Heart Failure Management: A Practical Guide to the Four Pillars and Beyond
8. American Heart Association, Treatment Options for Heart Failure